- AU$1.85bn
- AU$1.40bn
- AU$39.68m
Annual balance sheet for PYC Therapeutics, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 June 30th | 2026 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 29.1 | 15.6 | 66.9 | 153 | 448 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 10.1 | 16.3 | 18 | 24.1 | 34.1 |
| Prepaid Expenses | |||||
| Total Current Assets | 39.2 | 31.9 | 85.6 | 178 | 482 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 1.63 | 1.04 | 1.57 | 1.9 | 1.43 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 45.4 | 37.2 | 91.2 | 183 | 709 |
| Accounts Payable | |||||
| Payable / Accrued | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 4.39 | 8.41 | 9.11 | 12.3 | 14.4 |
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 6 | 9.42 | 10.7 | 13.7 | 15.2 |
| Common Stock | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | 39.4 | 27.7 | 80.5 | 170 | 693 |
| Total Liabilities & Shareholders' Equity | 45.4 | 37.2 | 91.2 | 183 | 709 |
| Total Common Shares Outstanding |